



Rec'd PCT/PTO 04 MAR 2003
PCT/GB 2003 / 0 0 3 8 6 7
10/526808
INVESTOR IN PEOPLE #2

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 20 OCT 2003

WIPO

PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

BEST AVAILABLE COPY

CERTIFIED COPY OF
PRIORITY DOCUMENT

Signed


R. Mahoney

Dated

7 October 2003

PRIORITY
DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)



0220936.9
1/77

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form.)

10SEP02 E747040-1 D01631
P01/7700 0.00-0220936.9
The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

Fee: £0

1. Your reference 44510/JMD

2. Patent application number
(The Patent Office will fill in this part) 0220936.9 - 5 SEP 2002

3. Full name, address and postcode of the or of each applicant (underline all surnames)

AdProTech Limited
Chesterford Research Park
Little Chesterford
Saffron Walden
Essex
CB10 1XL

Patents ADP number (if you know it)

7936123002

If the applicant is a corporate body, give the country/state of incorporation

UNITED KINGDOM

4. Title of the invention Modified Therapeutic Agents

5. Full name, address and postcode in the United Kingdom to which all correspondence relating to this form and translation should be sent

Reddie & Grose
16 Theobalds Road
LONDON
WC1X 8PL

Patents ADP number (if you know it)

91001 ✓

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application (if you know it)	Date of filing (day/month/year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of filing (day/month/year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

a) any applicant named in part 3 is not an inventor, or

b) there is an inventor who is not named as an applicant, or

c) any named applicant is a corporate body.

See note (d))

YES

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document.

Continuation sheets of this form

Description	28
Claim(s)	3
Abstract	RM
Drawing(s)	1 + 1

10. If you are also filing any of the following, state how many against each item.

Priority documents	0
Translations of priority documents	0
Statement of inventorship and right to grant of a patent (<i>Patents Form 7/77</i>)	0
Request for preliminary examination and search (<i>Patents Form 9/77</i>)	1 ✓
Request for substantive examination (<i>Patents Form 10/77</i>)	0
Any other documents (<i>please specify</i>)	

11. I/We request the grant of a patent on the basis of this application.

Signature

Date
4 September 2002

Reddie & Gorse

12. Name and daytime telephone number of person to contact in the United Kingdom
- J M DAVIES
01223 360350

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Modified Therapeutic Agents

This invention relates to modified therapeutic agents, their use in therapy and intermediates. More particularly it relates to soluble therapeutic agents containing membrane binding elements.

Many drugs are administered in a pharmaceutical solution with the drug dissolved in a physiological solution suitable for injection. Further, other drugs are administered in a dry form such as a tablet. In this form, the tablet dissolves after administration releasing the drug, which is absorbed into the bloodstream where it will be transported, by the blood, to its site of action. Whatever form the drug is administered in it is transported in soluble form within the bloodstream.

Biotechnology has increased the number of potential drugs that are proteins or protein based. Essentially all protein drugs are administered as solutions and function *in vivo* in the solution phase. In biochemistry and pharmacology, however, a large number of control and mediator proteins are associated with or function within or on the plasma membranes of cells. Except for soluble, truncated versions of one class of these molecules, no membrane-associated proteins have been developed as therapeutic agents. There are two main reasons for this situation. Firstly, overexpression of proteins that are retained in the membranes of the producer cells is limited by the low capacity of membranes for proteins and often by the toxic effects of retention when expression is intrinsically efficient. Secondly, extraction of these proteins from membranes requires detergents or organic solvents, often results in inactivation of the protein, leads to difficulties in achieving the high purity needed for drug use and usually gives a product which is hard to formulate for intravenous administration.

Soluble, truncated versions of membrane-associated proteins overcome the production difficulties associated with full length proteins. However such truncated molecules lack the membrane binding capability and specificity of the full length proteins which properties may be advantageous or even essential to the desired therapeutic activity. In addition, the biological action of other chemically derived drugs may benefit from being targeted to or within close proximity to, a cellular membrane.

WO 98/02454 describes a soluble derivative of a soluble polypeptide which comprises two or more heterologous membrane binding elements with low membrane affinity covalently associated with the polypeptide which elements are capable of interacting, independently and with thermodynamic additivity (Dill, K. A. J. Biol. Chem. 1997. 272, 701-704), with components of cellular or artificial membranes exposed to extracellular fluids ie. to the external surface of the cell or artificial membrane.

By 'heterologous' is meant that the elements are not found in the native full length protein from which a soluble protein may be derived.

By 'soluble polypeptide' is meant a truncated derivative of a full length protein which lacks its natural membrane binding capability, and/or a polypeptide which has a solubility level in aqueous media of $> 100\mu\text{g/ml}$.

By 'membrane binding element with low membrane affinity' is meant that the element has a measurable but relatively low affinity for membranes, that is a dissociation constant greater than $1\mu\text{M}$, preferably $1\mu\text{M}$ - 1mM . The elements preferably have a size $<5\text{kDa}$.

A modified therapeutic agent has sufficient membrane binding elements with low affinities for membrane

components to result in a derivative with a high (preferably 0.01 - 10nM dissociation constant) affinity for specific membranes. The elements combine so as to create an overall high affinity for the particular target membrane but the combination lacks such high affinity for other proteins for which single elements may be (low-affinity) ligands.

The elements should be chosen so as to retain useful solubility in pharmaceutical formulation media, preferably >100µg/ml.

Surprisingly, we have now found that an intermediate in the preparation of a modified therapeutic agent, namely three linked membrane binding elements, consisting of a basic amino acid element and two lipophilic elements remains soluble when prepared and isolated.

When modifying a therapeutic agent, the membrane binding elements can be added sequentially, with the first conjugated to the therapeutic agent, then subsequent elements being conjugated to each other. A second method of modifying the agent is to prepare the membrane binding elements separately, conjugate the elements to each other first, isolate the whole and then conjugate the preparation to the therapeutic agent.

When modifying peptides and proteins, the membrane binding element preparation (known as a "tail") is preferably soluble in aqueous solutions. This is to avoid the use of solvents to dissolve the tail prior to the conjugation to the peptide, which may damage the peptide. It is a surprising feature of the present invention that a tail with two lipophilic binding elements may be soluble in aqueous solution.

Further, when this soluble tail was added to a therapeutic agent the resultant modified therapeutic agent remained soluble.

In addition, it was found that a modified therapeutic agent containing this highly lipophilic tail had a lower affinity for serum albumin as compared to a therapeutic agent with only a single lipophilic membrane binding element. Under certain circumstances this reduced serum albumin affinity is preferable, potentially increasing the binding of the agent to cellular membranes.

The present invention therefore provides a modified therapeutic agent, said agent comprising three or more membrane binding elements wherein at least two elements are lipophilic.

The two lipophilic membrane binding elements may be different but preferably will be identical.

The lipophilic membrane binding elements are preferably a C₆₋₂₀ fatty acyl derivative of an amino C₂₋₆ alkane thiol (optionally C-substituted) such as N- (2-myristoyl) aminoethanethiol or N-myristoyl L-cysteine.

However, other elements will be known to those in the art. In general the lipophilic membrane binding element is defined as;

having from 6 to 30, carbon atoms including those of any aromatic rings, if present;
being straight or branched (for example having two or three branch points);
saturated or unsaturated (for example containing one or more double or triple bonds);
having one or more (such as 1, 2, 3 or 4) heteroatoms independently selected from S, O, or N;

optionally, containing one or more, for example two or three aromatic rings, which may or may not be fused and each of which may contain from one or more (such as 1, 2, 3 or 4) heteratoms which, if present, are independently selected from N, O, or S and; optionally having one or more (such as 1, 2, or 3) substituents selected from hydroxy, -SH, amino and halo (where halo is fluoro, chloro, bromo or iodo).

Preferably, the aromatic rings are six-membered, and may be selected from benzene and pyridine. If the rings are fused, then they may be selected from naphthalene, anthracene, quinolene and isoquinolene. Other examples of aromatic rings include thiophene and pyrrole.

The therapeutic agent can be a therapeutic protein or peptide. A therapeutic protein is a protein that has a biological effect on a region in the body on which it acts or on a region of the body on which it remotely acts via intermediates. The invention thus promotes localisation of such a therapeutic protein at cellular membranes and thereby provides one or more of several biologically significant effects with potential therapeutic advantages.

In this specification to terms polypeptide, protein and peptide are synonymous and are used interchangeably. The term therapeutic protein is the term used to define a protein, polypeptide or peptide that has a therapeutic effect when administered to the body.

Most importantly, the modifying lipophilic tail promotes localisation of the therapeutic agent to cellular membranes without significant binding to blood serum albumin and thereby reduces the amount of protein lost to indirect serum binding and increases the amount that is available to bind to the desired cellular membrane.

A modified therapeutic agent as described may be used in association with artificial membranes or mimics thereof to allow delivery of the therapeutic agent to sites where it will provide therapeutic benefit.

Examples of therapeutic proteins that may be modified according to the invention include but are not limited to the following:

Table 1: Therapeutic Proteins

Base Protein	Cell Target	Therapeutic Application
IL-4 Y124D mutein	B-cells	Anti-allergy (IL-4 antagonist)
Plasminogen activators e.g. Prourokinase, streptokinase, tissue-type plasminogen activator, reteplase	Erythrocytes, vascular endothelium	Prevention of venous thrombosis
Leptin	Choroid plexus, Hypothalamus	Weight loss (agonist)
Complement inhibitors*	Vascular endothelium, Myocytes, Erythrocytes, Lymphocytes	Ischaemic injury, transplantation inflammation
scFv antibody against cytokines	Eosinophils	Asthma, Allergic disease
Protein C	Vascular endothelium	Prevention of venous thrombosis
Antibodies against CD4, B7/CD28, CD3/TCR, CD11b (CR3)	Lymphocytes	Immunosuppression
Interferon- β and derivatives	Lymphocytes	Immunomodulation, Multiple sclerosis

*CR1 (CD35); DAF (CD55); MCP (CD46); CD59; Factor H C4 binding protein; and hybrids or muteins thereof such as CR1-CD59 chimeras.

Examples of non-protein therapeutic agents include but are not limited to anti-infectives such as antibacterial, antimicrobial, and antifungal agents such as amphotericin; cytotoxic agents such as paclitaxel and doxorubicin; corticosteroids agents such as dexamethasone; other cell

surface acting therapeutic agents will be well known to those in the art.

Importantly the invention comprises two (or more) lipophilic membrane binding elements. However, additional membrane binding elements are preferably selected from: basic amino acid sequences; ligands of known integral membrane proteins; sequences derived from the complementarity-determining region of monoclonal antibodies raised against epitopes of membrane proteins; membrane binding sequences identified through screening of random chemical or phage display libraries.

Suitable examples of amino acid sequences comprising basic amino acids include:

- i) DGPKKKKKKSPSKSSGC [SEQ ID NO: 1]
- ii) GSSKSPSKKKKKKPGDC [SEQ ID NO: 2]
- iii) SPSNETPKKKKKRFSFKKSG [SEQ ID NO: 3]
- iv) CDGPKKKKKKSPSKSSK [SEQ ID NO: 4]
- v) SKDGKKKKKKSKTKC [SEQ ID NO: 5]
- vi) GSSKSPSKKDDKKGDC [SEQ ID NO: 6]
- vii) GSSKSPSKDKDKDGDC [SEQ ID NO: 7]
- viii) KSSKSPSKKDDKKPGDC [SEQ ID NO: 8]
- ix) KSSKSPSKDKDKDPGDC [SEQ ID NO: 9]

(N-terminus on left)

In addition, it would be envisaged that smaller basic elements could be used that still retain the necessary properties of the invention, for example KSKKKC [SEQ ID NO: 10]. These would have a number of advantages including the cost of production of modified therapeutic agent incorporating such peptide sequence.

Examples of amino acid sequences derived from ligands of known integral membrane proteins include RGD-containing

peptides such as GRGDSP [SEQ ID NO: 11] which are ligands for the $\alpha_{IIb}\beta_3$ integrin of human platelet membranes. Another example is DGPSEILRGDFSSC [SEQ ID NO: 12] derived from human fibrinogen alpha chain, which binds to the GpIIb/IIIa membrane protein in platelets.

Further examples of such sequences include those known to be involved in interactions between membrane proteins such as receptors and the major histocompatibility complex. An example of such a membrane protein ligand is the sequence GNEQSFRVDLRTLRLRYA [SEQ ID NO: 13] which has been shown to bind to the major histocompatibility complex class 1 protein (MHC-1) with moderate affinity.

Yet further examples of such sequences employ a membrane insertive address specific for T-cells. Such a sequence is derived from the known interaction of the transmembrane helix of the T-cell antigen receptor with CD3. Examples are peptides containing the sequence GFRILLKV [SEQ ID NO: 14].

An example of a ligand for an integral membrane protein is the carbohydrate ligand Sialyl Lewis^x which has been identified as a ligand for the integral membrane protein ELAM-1.

Sequences derived from the complementarity-determining regions of monoclonal antibodies raised against epitopes within membrane proteins are also suitable membrane binding elements, as are binding sequences from random chemical libraries such as those generated in a phage display format and selected by biopanning operations *in vitro*.

Optionally, conditional dissociation from the membrane may be incorporated into agents of the invention using mechanisms such as pH sensitivity, regulation through metal ion binding (using endogenous Ca^{2+} , Zn^{2+} and incorporation of ion binding sites in membrane binding elements) and

protease cleavage (e.g plasminolysis of lysine-rich membrane binding sequences to release and activate prourokinase).

Peptidic membrane binding elements are preferably located sequentially either at the N or C terminus of the agent. The amino acid sequences are linked to one another and to the soluble agent by linker groups which are preferably selected from hydrophilic and/or flexible amino acid sequences of 4 to 20 amino acids; linear hydrophilic synthetic polymers; and chemical bridging groups. They can also be linked directly via a suitable bond such as the native amide bond.

Peptides and peptide linkages may be made chemically or biosynthetically by expression of appropriate coding DNA sequences. Non peptide linkages may be made chemically or enzymatically by post-translational modification.

Chemical bridging groups and reagents suitable for their formation are known to those skilled in the art. For example, where the polypeptide portion of the agent of the invention and a peptidic membrane binding element both include a single cysteine the linkage between the two will take the form -S-S-. This is generated by conventional disulphide exchange chemistry, by activating a thiol on one polypeptide and reacting the activated thiol with a free thiol on the other polypeptide. Such activation procedures make use of disulphides which form stable thiolate anions upon cleavage of the S-S linkage and include reagents such as 2,2' dithiopyridine and 5,5'-dithio(2-nitrobenzoic acid, DTNB) which form intermediate mixed disulphides capable of further reaction with thiols to give stable disulphide linkages.

Also, a free thiol function can be introduced by reaction of a polypeptide with 2-iminothiolane, N-succinimidyl 3-(2-

pyridyldithio) propionate (with subsequent reduction) or N-acetyl homocysteine thiolactone. This will permit coupling of the protein attachment group with a thiol-reactive group. Alternatively, the protein attachment group can contain a thiol-reactive entity such as the 6-maleimidohexyl group or a 2-pyridyl-dithio group which can react with a free thiol. Preferably, the protein attachment group is derived from protein modifying agents such as 2-iminothiolane that react with lysine ϵ -amino groups in proteins.

After the linkage reaction, the conjugate can be isolated by a number of chromatographic procedures such as gel filtration, ion-exchange chromatography, affinity chromatography or hydrophobic interaction chromatography. These procedures may be either low pressure or high performance variants.

The conjugate may be characterised by a number of techniques including low pressure or high performance gel filtration, SDS polyacrylamide gel electrophoresis or isoelectric focussing.

The agents of this invention are preferably administered as pharmaceutical compositions.

Accordingly, the present invention also provides a pharmaceutical composition comprising an agent of the invention and a pharmaceutically acceptable excipient.

The quantity of material administered will depend upon the potency of the agent and the nature of the complaint be decided according to the circumstances by the physician supervising treatment. However, in general, an effective amount of the polypeptide for the treatment of a disease or disorder is in the dose range of 0.01-100mg/kg per day,

preferably 0.1mg-10mg/kg per day, administered in up to five doses or by infusion.

The invention also provides an agent of the invention for use as a medicament.

The invention further provides a method of treatment of disorders amenable to treatment by a therapeutic agent which comprises administering a modified therapeutic agent according to the invention, and the use of an agent of the invention for the preparation of a medicament for treatment of such disorders.

Drawings

Figure 1. A graph of percentage inhibition of haemolysis in the presence (empty symbol) or absence (filled symbol) of serum albumin. -◇- APT070 (single myristoyl group), and -Δ- APT3098 (two lipophilic (myristoyl) elements).

Note: APT070 is the composition [SCR1-3]-Cys-S-S-[MSWP-1]
SEQ ID NO: 8 of Example 8 of WO98/02454.

Examples

Synthesised bis acylated membrane binding tails

The following compounds were synthesised each containing two fatty acid membrane binding elements and a basic element. The fatty acid membrane binding element consisted of either a Myristoyl, Hexanoyl or Decanoyl group.

Table 2: Binding Membrane Element Reference No.

Peptide	Sequence	SEQ ID No.
APT3098	bis-myristoyl-KSSKSPSKDDKKPGDC	15
APT3328	bis-myristoyl-KSSKSPSKDKDKDPGDC	16
APT3329	bis-myristoyl-KSKKKC	17
APT3330	bis-Decanoyl-KSSKSPSKDDKKPGDC	18
APT3331	bis-Decanoyl-KSSKSPSKDKDKDPGDC	19
APT3332	bis-Decanoyl-KSKKKC	20
APT3333	bis-Hexanoyl-KSSKSPSKDDKKPGDC	21
APT3334	bis-Hexanoyl-KSSKSPSKDKDKDPGDC	22
APT3335	bis-Hexanoyl-KSKKKC	23

The bis acylated (underivatised) peptides were activated via thiopyridylation by reaction with Aldrithiol-2.

Aldrithiol-2 (110.2 mg, 500 μ mol) was dissolved in acetonitrile (2 mL) to yield a 250 mM solution. Each of the underivatised peptides (see below for amounts) was dissolved in water (1 mL) and 3 equivalents of Aldrithiol-2 (in solution) were added.

The reaction mixtures were stirred for 2 h.

Purification of APT3328, APT3333, APT3334, APT3335

The target molecule was isolated by preparative HPLC and the majority of the solvent was removed under reduced

pressure to leave ~2 mL of aqueous solution. This solution was lyophilised to yield a fluffy white solid.

Purification of APT3329

The target molecule was isolated by preparative HPLC and the majority of the solvent was removed under reduced pressure, causing a white solid to precipitate out of solution. DMSO (2 mL) was added to dissolve the precipitate and the remaining water removed under reduced pressure.

Purification of APT3330, APT3331 and APT3332

The target molecule co-eluted with excess Aldrithiol-2 upon preparative HPLC. The majority of the solvent was removed under reduced pressure to leave ~2 mL of aqueous solution, which was transferred to a lyophilisation vial (10 mL size). Ethyl acetate (2 mL) was added, the vial shaken and the aqueous/organic layers left to separate. The organic (top) layer was removed using a Pasteur pipette. This extraction process was repeated three times (3 x 2 mL ethyl acetate) and the target molecule isolated by preparative HPLC. The majority of the solvent was removed under reduced pressure to leave ~2 mL of aqueous solution. This solution was lyophilised to yield a fluffy white solid.

Conjugation of membrane binding peptide to SCR1-3 (APT154)

The bis acylated membrane binding peptides were conjugated to SCR1-3 (APT154) using activated peptides.

APT154 solution (100 μ M, 5 mL, 0.5 μ mol) in sodium phosphate buffer (0.1 M, pH 6.0) was reduced with TCEP (1.5 μ mol, 150 μ L of a 10 mM stock, 3 equivalents) by leaving overnight at room temperature.

APT154 (60 nmol, 600 μ L of the reduced stock solution, allowing for a final concentration of 40 μ M in 1.5 mL) was added to each of activated peptide (10 equivalents, 600 nmol in DMSO). Citrate buffer (pH 6.0, 808.4 μ L) was added to the eight reaction mixtures to make the volume up to 1.5 mL in each.

The mixtures were left for 2 h at RT. Conjugation was assessed by SDS-PAGE.

The SDS-PAGE showed that APT3329, 3332, and 3335 had not successfully conjugated.

Anti-haemolytic assays

The Anti-complement activity of the modified SCR1-3 agents was measured by classical pathway mediated haemolysis of sheep erythrocytes.

Anti-complement activity of acylated peptide / APT154 conjugates

Step 1 - The Dilution Plate

7 wells of each of 9 lanes, missing the uppermost well, on a flat-bottomed microtitre plate were filled with 200 μ L of diluent (0.100 M Hepes, 0.150 M NaCl, 0.100% gelatin, adding NaOH to pH 7.4).

Into the uppermost wells, the required volume of each test/control sample was aliquotted, immediately followed by enough diluent to make the total volume up to 300 μ L, to ensure a final concentration of 1.2 μ M.

Using a multichannel Gilson pipette, all 9 top wells were mixed and 100 μL were transferred from these wells to the corresponding wells in 2nd row.

Using the multichannel Gilson pipette, and after mixing thoroughly, a further 22 μL was transferred from the 2nd row into the 4th, 22 μL from the 4th row to the 6th and a further 22 μL was transferred from the 6th row to the 8th.

Similarly 22 μL from wells in the top row were transferred to the 3rd, 22 μL from those in the 3rd row to the 5th and finally 22 μL from the 5th row were transferred to the 7th, creating a 3 log dilution gradient. At each step it was made sure that the wells were mixed thoroughly.

Step 2 - The reaction plate

Using a multichannel Gilson 100 μL of diluent were pipetted into all wells of column A on two V-bottomed microtitre plate and 50 μL of diluent into all wells of column B. These lanes formed the background (A_0) and 100% (A_{max}) controls. 50 μL from each well of the APT154 dilution series (lane 1 of the dilution plate) were transferred into lanes 3 and 4 of the first reaction plate. Each sample was tested in duplicate on the reaction plate. This procedure was repeated for the remaining samples.

15.8 mL of diluent and 160 μL of pig serum was mixed by swirling in a polypropylene universal tube. This diluted serum was tipped into a square petri dish (100 x 100 mm). 50 μL of this solution was transferred to each well of the two reaction plates, except for the wells of each column A, using the multichannel Gilson pipette.

8 tubes (4 for each reaction plate) of sensitised sheep red blood cells were shaken rapidly for a few seconds to

resuspend the cell pellet until the solution was a uniform pink colour. These were emptied into a new 100 x 100 mm petri dish and were mixed by swirling the tray gently. Using the multichannel Gilson, 100 μ L of the RBC suspension was transferred into each well of the two reaction plates.

Precut pieces of Nescofilm were placed across the open wells of the two reaction plates and were incubated at 37°C for 1 hour, without shaking.

Step 3: Processing of Plate

After incubation the plates were centrifuged at 1600 rpm for 3 min and the Nescofilm removed. 150 μ L of supernatant from each well of the two plates was then transferred into the corresponding wells of two new microtitre plates and the absorbance of each well measured at 405 nm using a plate reader.

Calculation of % inhibition

% inhibition was calculated using the following formula:

$$1 - \left(\frac{t - A_o}{A_{max} - A_o} \right) \times 100\%$$

wherein:

A_o = the mean value of the absorbances in lane 1

A_{max} = the mean value of the absorbances in lane 2

t = the mean of the two absorbance values for each sample at any given concentration.

Haemolytic Assay data

The table below shows the percentage inhibition average data from both assays (i.e. four wells of the reaction plates) for each polypeptide.

Average absorbances at 405 nm

$A_o = 0.033$ $A_{max} = 0.204$

Table 3: Percentage inhibition of haemolysis for modified therapeutic agents

Conc / nM	Compound					
	APT154	APT3328	APT3330	APT3331	APT3333	APT3334
300	112.66	106.74	110.44	105.85	107.48	110.29
100	97.11	106.14	103.48	108.96	101.41	98.59
30	73.58	107.33	106.88	106.59	69.13	68.39
10	45.00	87.19	105.40	106.29	38.79	42.93
3	32.12	48.56	100.96	91.93	14.66	17.02
1	8.88	37.45	80.53	64.84	15.25	10.21
0.3	3.11	15.69	43.97	29.61	17.76	7.55
0.1	7.40	5.33	23.09	19.84	8.44	8.59

The assay showed that the addition of the various membrane binding elements did not greatly affect the activity of the SCR1-3 peptide.

Anti-complement activity of acylated peptide / APT154 conjugates in the presence of bovine serum albumin (BSA)

Step 1 - The Dilution Plate

BSA (320 mg) was dissolved in diluent (20 mL, 0.100 M Hepes, 0.150 M NaCl, 0.100% gelatin, adding NaOH to pH 7.4). 7 wells of each of 4 lanes, missing the uppermost well, on a flat-bottomed microtitre plate were filled with 200 μ L of the BSA / diluent solution. Into the uppermost wells, the required volume each test/control sample (APT3328, APT3330, APT3331 and APT070) was aliquotted, immediately followed by enough BSA / diluent solution to make the total volume up to 300 μ L, to ensure a final concentration of 1.2 μ M.

These 1.2 μ M wells were then diluted across a 3 log dilution gradient and the rest of the assay performed as for the peptide/APT154 conjugates. The BSA diluent solution was used instead of pure diluent except for the A_0 lane of the reaction plate, for which pure diluent (50 μ L) and the BSA / diluent solution (50 μ L) were aliquotted. The whole assay was repeated.

Haemolytic Assay data

The two tables (Table 4 and 5) below show the average data from both assays (i.e. four wells of the reaction plates)

Average absorbances at 405 nm

$$A_0 = 0.040 \quad A_{\max} = 0.184$$

Table 4: Average absorbance data for modified therapeutic agents with BSA.

Conc / nM	Compound			
	APT070	APT3328	APT3330	APT3331
300	0.042	0.051	0.049	0.060
100	0.050	0.052	0.051	0.056
30	0.064	0.093	0.075	0.066
10	0.069	0.131	0.111	0.120
3	0.143	0.163	0.171	0.176
1	0.168	0.186	0.182	0.183
0.3	0.189	0.198	0.192	0.202
0.1	0.199	0.205	0.190	0.193

Table 5: Average % Inhibition for modified therapeutic agents with BSA

Conc / nM	Compound			
	APT070	APT3328	APT3330	APT3331
300	98.84	93.02	94.35	86.53
100	93.35	92.02	92.85	89.69
30	84.21	64.92	76.56	82.54
10	80.71	39.65	52.62	46.80
3	31.50	18.20	12.88	9.73
1	14.88	3.24	5.57	4.90
0.3	1.08	-5.07	-0.91	-7.56
0.1	-5.40	-9.39	0.58	-1.91

Anti-complement activity of acylated peptide / APT154 conjugates in the absence and presence of BSA

Absence of BSA

Step 1 - The Dilution Plate

7 wells of each of 5 lanes, missing the uppermost well, on a flat-bottomed microtitre plate were filled with 200 μ L of diluent (0.100 M Hepes, 0.150 M NaCl, 0.100% gelatin, adding NaOH to pH 7.4).

Into the uppermost wells, the required volume of each test/control sample was aliquotted, immediately followed by enough diluent to make the total volume up to 300 μ L, to ensure a final concentration of 1.2 μ M.

The specific volumes of each sample used, along with the designated lanes for each are shown below.

These 1.2 μM wells were then diluted across a 3 log dilution gradient and the rest of the assay performed as for the peptide/APT154 conjugates.

Presence of BSA

The method used was as that above for the assay in the absence of BSA, using BSA / diluent solution (160 mg BSA in 10 mL diluent) instead of pure diluent. In the A_0 lane of the reaction plate, for which pure diluent (50 μL) and the BSA / diluent solution (50 μL) were aliquotted.

Haemolytic assay data

Average absorbances at 405 nm

No BSA $A_0 = 0.025$ $A_{\text{max}} = 0.213$

With BSA $A_0 = 0.057$ $A_{\text{max}} = 0.190$

Table 6: Average absorbance data for modified therapeutic agents without BSA.

Conc/ nM	Without BSA				
	APT070	APT3098	APT3328	APT3330	APT33331
300	0.025	0.025	0.016	0.026	0.019
100	0.021	0.021	0.024	0.025	0.025
30	0.046	0.028	0.061	0.018	0.021
10	0.019	0.058	0.099	0.023	0.042
3	0.069	0.142	0.173	0.031	0.041
1	0.036	0.178	0.203	0.093	0.109
0.3	0.075	0.226	0.221	0.162	0.170
0.1	0.155	0.217	0.222	0.188	0.185

$A_0 = 0.025$ $A_{\text{max}} = 0.213$

Table 7: Average % Inhibition data for modified therapeutic agents without BSA.

Conc / nM	Without BSA				
	APT070	APT3098	APT3328	APT3330	APT3331
300	100.00	100.00	104.79	99.73	103.46
100	102.13	102.13	100.80	100.27	100.00
30	88.83	98.40	81.12	103.72	102.13
10	103.19	82.45	60.64	101.33	91.22
3	76.60	37.77	21.28	96.81	91.76
1	94.15	18.62	5.59	63.83	55.32
0.3	73.40	-6.91	-3.99	27.13	22.87
0.1	30.85	-2.13	-4.79	13.56	15.16

Table 8: Average Absorbance data for modified therapeutic agents with BSA.

$A_0 = 0.057$

$A_{max} = 0.190$

Conc / nM	With BSA				
	APT070	APT3098	APT3328	APT3330	APT3331
300	0.086	0.051	0.060	0.041	0.059
100	0.054	0.062	0.046	0.057	0.062
30	0.078	0.048	0.086	0.074	0.063
10	0.097	0.084	0.157	0.106	0.143
3	0.119	0.105	0.168	0.167	0.168
1	0.175	0.172	0.195	0.191	0.201
0.3	0.210	0.187	0.203	0.224	0.203
0.1	0.203	0.226	0.211	0.224	0.218

Table 9: Average % Inhibition for modified therapeutic agents without BSA.

Conc / nM	With BSA				
	APT070	APT3098	APT3328	APT3330	APT3331
300	77.96	104.57	97.45	111.69	98.58
100	101.95	95.95	107.95	100.07	96.33
30	84.33	106.82	77.96	86.96	95.20
10	70.09	79.84	25.11	62.97	35.23
3	53.22	63.72	16.49	17.24	16.49
1	11.62	13.87	-3.75	-0.75	-8.25
0.3	-14.99	2.25	-9.75	-25.49	-9.37
0.1	-9.37	-26.61	-15.74	-25.49	-20.61

The data shows that the modified therapeutic agents retain activity following modification. The IH50 of a compound is the compound's concentration at which 50% inhibition of haemolysis of the erythrocytes is measured. This can be used as an indicator to the efficacy of the complement inhibitor.

The table below shows the IH50 of the tested compounds in the presence or absence of serum albumin.

Table 10: IH50 values for modified therapeutic agents

Compound	IH50 (nM)	
	Absence of Albumin	Presence of Albumin (40mg/ml)
APT070 control	0.26	10.0
APT3098	4.2	3.2
APT3328	7.0	10.1
APT3330	0.65	7.0
APT3331	0.83	14.0

Hence in the presence of albumin the IH50 those agents with two lipophilic membrane binding elements according to the

invention retained their activity to a greater extent than the APT070 control ie were less affected by the presence of albumin.

Example 2:

Bis-myristoylated CD59

CD59 is one of a number of complement system's regulators that prevents inappropriate activation. This regulator blocks the lytic activity of complement by binding to the C5b-8 and C5b-9 complexes and preventing formation of the polymeric C9 complex during the final stages of membrane attack complex (MAC) assembly on cell membranes. Human CD59 is a widely distributed glycoprotein which is anchored to the cell membrane via a glycosphosphoinositol (GPI) moiety.

Expression of Recombinant human CD59 (APT2439)

Recombinant human CD59 (lacking the GPI anchor), with an amino-terminal methionine and a carboxy-terminal cysteine (APT2439) was expressed in *E. coli*. The expression was codon optimised and under control of the T7 promoter, so that in the appropriate *E. coli* host strain, a λ DE3 lysogen, the addition of the inducer iso-propyl β -D-thiogalactopyranoside (IPTG) to 1mM resulted in expression of the target gene.

Refolding and Purification of APT2439

An *E. coli* cell pellet containing APT2439 as inclusion bodies was resuspended in a buffer containing 50mM Tris, 1mM EDTA, 0.1M NaCl adjusted to pH 8.0 with HCl, and lysed by two passages through an Emulsiflex C5 high pressure homogeniser (Glen Creston, UK) at 12000psi. The inclusion bodies were isolated by centrifugation and purified by resuspension in a buffer containing 2% sodium deoxycholic

acid and centrifugation as described above. This procedure was repeated several times. The purified inclusion bodies were solubilised in a buffer containing 8M urea, 5mM dithiothreitol, 50mM Tris, 1mM EDTA, adjusted to pH 8.0 with HCl. Remaining insoluble material was removed by centrifugation. APT2439, contained in the supernatant, was refolded by diluting 50-fold into a buffer containing 50mM Tris, 1mM EDTA, 0.5M arginine, 3mM cysteine, 1mM cystine, adjusted to pH 8.0 with HCl, and incubation at 2-8°C for 24 to 96 hours. The refolded protein was concentrated by ultrafiltration and extensively diafiltered against phosphate buffered saline at pH 7.3. Ammonium sulphate was added to a final concentration of 2.2M. Aggregated and misfolded protein was removed by centrifugation as describe above. The purified protein was diluted to reduce the concentration of ammonium sulphate and concentrated by ultrafiltration to about 100 μ M.

Conjugation of APT2439 to APT2258 or APT3146.

The purified APT2439 was treated for 16 hours at room temperature with two molar equivalents of the reducing agent tris-2-carboxyethyl phosphine (TCEP), to generate a free thiol on the carboxy terminal cysteine of the protein. The protein was then incubated for two hours at room temperature with three molar equivalents of either APT2258 (Myr-GSSKSPSKDDKKPGDC(2-SPy)-NH₂; SEQ ID NO: 24) or APT3146 (thiopyridylated bisMyr-KSSKSPSKDDKKPGDC; SEQ ID NO: 25). The conjugation of APT2439 and APT2258 via a disulphide resulted in the formation of APT3073. The conjugation of APT2439 and APT3146 via a disulphide resulted in the formation of APT3280.

Purification of APT3073 and APT3280.

Ammonium sulphate was added to the conjugation mixtures described above (1.5M in the case of APT3073 and 1.0M in

the case of APT3280) and the conjugates were purified by application to Toyopearl Phenyl 650M (Tosoh). The proteins were eluted in a linear decreasing gradient of ammonium sulphate.

Activity of APT2439, APT3073 and APT3280.

The ability of APT2439, APT3073 and APT3280 to inhibit MAC formation on guinea pig erythrocytes, was tested in a reactive lysis system. The effect of human albumin (HSA) on this activity was also investigated. Test samples were prepared at a range of concentrations in the presence or absence of 8mg/ml fatty acid free HSA (Sigma, UK). 50 μ L of these dilutions was added to 50 μ L of a 5% suspension of guinea pig erythrocytes in PBS/0.1% gelatin, and incubated for 30 minutes at 37°C. 10 μ L of human C5b6 complex (C5b6 was partially purified from acute phase serum) in PBS containing 15mM EDTA and 0.1% gelatin, was added to the guinea pig erythrocyte suspension. 40 μ L of normal human serum, diluted in PBS containing 15mM EDTA and 0.1% gelatin was added as a source of C7, C8 and C9, and the suspension was incubated for 1 hour at 37 degrees Celsius. (The concentrations of C5b6 and normal human serum required to achieve about 80% lysis of guinea pig erythrocytes was pre-determined by titration.) The reaction mixtures were centrifuged for 5 minutes at 1000xg and the degree of haemolysis was determined by measuring the absorbance of the supernatant at 410nm. To determine background lysis, a control reaction was prepared without serum. To determine maximal lysis, a control reaction containing no inhibitor (or test sample) was prepared. The percentage inhibition of haemolysis was determined for each protein at each concentration. An IH50 value (the concentration of protein required to achieve 50% inhibition of lysis) was determined for each protein in the presence and absence of HSA. IH50 values are presented in Table 11.

Table 11: IH50 values for modified therapeutic agent in the presence or absence of HSA.

Agent	IH50 (nM)	
	Absence of HSA	Presence of HSA (2.7mg/ml)
APT2439	600	400
APT3073	0.8	6
APT3280	0.1	0.08

In the absence of HSA, APT2439 was required at mM concentrations to achieve complete inhibition of haemolysis in the reactive lysis assay. APT3073 and APT3280 demonstrated about a 3-log and 4-log increase in potency respectively, compared to APT2439. In the presence of HSA (at a final concentration of 2.7mg/ml) APT3073 demonstrated a 1-log decrease in potency compared to its potency in the absence of HSA. APT2439, APT3280 did not demonstrate any decrease in potency in the presence of HSA.

Example 3:

Repeat of Bis-myristoylated SCR1-3

Conjugation.

SCR1-3 (APT154) was modified with bismyristoyl as detailed above. APT154 was incubated overnight in 3-fold excess TCEP, then incubated for 2 hours with APT3146 (bis myristoyl) at a 10-fold excess. APT154 when derivatised with two myristoyl groups (APT 3147; bismyr-GSSKSPSKKKKKPGDC conjugated to SCR1-3 ;SEQ ID NO: 26) was soluble under standard conditions. The activity of the conjugate was measured using the methods detailed above and summarised below.

Activity.

Multiple anti-haemolytic assays were performed on the reaction mixture of more than one batch of APT3147, in the presence and absence of fatty acid free bovine serum albumin (BSA) at both 4mg/ml and 40mg/ml, on non-stick plates.

The activity of both APT070 (single lipophilic membrane binding element) and APT3147 (two lipophilic membrane binding elements) was measured. The activity of APT3147 was less than APT070 in the absence of BSA, having IH50's of 0.26 and 2.2 respectively.

However, the activity of APT3147 was not affected by the presence of BSA even at a concentration of 40mg/ml maintaining an IH50 of 2.2. By comparison, the activity of APT070 was reduced at a concentration of 4 and 40mg/ml BSA to 1.3 and 10 respectively.

Table 12: Comparison of IH50 of a modified SCR1-3 with a single lipophilic element and two lipophilic elements.

Compound	No BSA	4mg/ml BSA	40mg/ml BSA
APT070	0.26	1.3	10
APT3147	2.2	2.2	2.2

Example 4: Vancomycin conjugates

The lipophilic/basic tails were conjugated to Vancomycin by reaction with APT2033 (pyridyl dithioethyl Vancomycin carboxamide)

To each of nine tails APT2033 (3 equivalents) dissolved in water (1 mL) was added.

The nine reaction mixtures were stirred for 2 h at RT and the target compounds isolated by preparative HPLC. The majority of the solvent from each of the nine compounds was removed under reduced pressure to leave ~ 2 mL aqueous solution for each, which were lyophilised to yield fluffy white solids.

MIC data

The activity of the modified Vancomycin was tested against two strains of bacteria.

MICs with *Bacillus subtilis* ATCC 6633 and *S. aureus* in NBS plate ($\mu\text{g/ml}$)

Agent	<i>B. subtilis</i>	<i>S. aureus</i>
APT3098	>128	>128
APT3328	32	>128
APT3329	128	>128
APT3330	0.25	8
APT3331	1	8
APT3332	<0.063	<0.063
APT3333	8	>128
APT3334	32	>128
APT3335	0.125	4

The results showed that the modified Vancomycin compounds retained activity the most effective being APT3332.

Claims

1. A modified therapeutic agent, said modified agent comprising three or more membrane binding elements with low membrane affinity covalently associated with the agent which elements are capable of interacting independently and with thermodynamic additivity, with components of cellular or artificial membranes exposed to extracellular fluids wherein at least two membrane binding elements are lipophilic elements.
2. An agent according to claim 1 wherein the lipophilic elements are aliphatic acyl groups.
3. An agent according to any of claim 1 - 2, wherein the aliphatic acyl group is selected from the list consisting of Myristoyl, Decanoyl or Hexanoyl.
4. An agent according to any of claim 1 - 3 wherein the two lipophilic elements are identical.
5. An agent according to any of claims 1 - 4 wherein the lipophilic elements are Myristoyl.
6. An agent according to any of claims 1 - 5 wherein the agent is a soluble protein.
7. An agent according to claim 6 wherein the soluble protein is a complement inhibitor.
8. An agent according to any of claims 1 - 5 wherein the agent is an anticancer agent.
9. An agent according to any of claims 1 - 5 wherein the agent is an antibacterial agent.

10. An agent according to claim 9 wherein the agent is Vancomycin.
11. An agent according to any of claim 1 - 10 wherein the agent contains two myristoyl groups and a basic amino acid sequence selected from the group consisting of:
 - GSSKSPSKKKKKKPGDC [SEQ ID NO: 2];
 - GSSKSPSKKDDKKGDC [SEQ ID NO: 6];
 - GSSKSPSKDKDKDGDC [SEQ ID NO: 7];
 - KSSKSPSKKDDKKPGDC [SEQ ID NO: 8];
 - KSSKSPSKDKDKDPGDC [SEQ ID NO: 9]; or
 - KSKKKC [SEQ ID NO: 10]
12. A pharmaceutical composition comprising an agent according to any of claims 1 - 11 and a pharmaceutically acceptable excipient.
13. An agent according to any of claim 1 - 12 wherein the agent is for use as a medicament.
14. An isolated intermediate for the preparation of a modified therapeutic agent comprising a conjugate consisting of two lipophilic membrane binding elements and a basic amino acid sequence.
15. An isolated intermediate according to claim 14 wherein the lipophilic elements are Myristoyl.
16. An isolated intermediate according to claim 14 - 15 wherein the basic amino acid sequence is selected from KSSKSPSKKDDKKPGDC [SEQ ID NO: 8] or KSSKSPSKDKDKDPGDC [SEQ ID NO: 9].
17. A method of treatment of a disease or disorder amenable to treatment by a soluble therapeutic agent which comprises administering a modified therapeutic agent according to any of claim 1 - 11.

18. The use of an agent according to any of claim 1 - 11
for the preparation of a medicament for treatment of a
disease or disorder.




Figure 1

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record.**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.